lifestyle.smsolar.net

Author: Tarsus Pharmaceuticals, Inc

Tarsus to Report First Quarter 2026 Financial Results on Wednesday, May 6, 2026

April 29, 2026
Tarsus Doses First Participant in Calliope, A Phase 2 Clinical Trial of TP-05 (lotilaner), a Novel Investigational Oral Tablet for the Potential Prevention of Lyme Disease

March 31, 2026
TP-03 (lotilaner ophthalmic solution) 0.25% Now Approved in China for the Treatment of Demodex Blepharitis, Triggering a $15M Milestone Payment to Tarsus

March 23, 2026
Tarsus to Participate in Upcoming Investor Conferences

February 26, 2026
Tarsus Reports Fourth Quarter and Full-Year 2025 Financial Results and Recent Business Achievements

February 23, 2026
Tarsus Pharmaceuticals Appoints Renowned Biopharmaceutical Leader and Former Allergan CEO, David Pyott, to its Board of Directors

February 18, 2026
Tarsus to Report Fourth Quarter and Full Year 2025 Financial Results on Monday, February 23, 2026

February 17, 2026